Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
null
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
null
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
null
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
undefined
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation
#Partners
חברת הטלה-רפואה Hims&Hers הודיעה כי תשווק גרסה משלה לגלולה ווגובי, אך בסופו של דבר ויתרה על המהלך ● בעקבות המלחמה עלה הצורך בטיפול ב"קעקועים טראומטיים" הנגרמים מחדירת רסיסים לעור ● חברת Launch One Acquisition Corp הודיעה כי בסופו של דבר היא לא תמזג לתוכה את חברת מינוביה הישראלית ● חברת ההשקעות ביומד אופקו מרחיבה את שיתוף-הפעולה עם אנטרה ● וכך קופ"ח מכבי מתכוונת להגן על טמפרטורת התרופות ● השבוע בביומד
#Product Stage #FDA approved/pending approval
Opko Health (OPK) Expands Entera Partnership for Drug Co-Development
#Partners
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
#Product Stage #Partners #Management Changes
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
#Product Stage #Partners
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
#Product Stage #Partners
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
#Product Stage #Partners
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
#Product Stage #Partners
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
#Partners
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
#Product Stage #Partners
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
#Product Stage #Partners
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
#Product Stage #Partners
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
#Acquisition #Partners
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
undefined
Opko jumps on Covid-19 diagnostic lab announcement
#Customers #Investment
Opko Health seeks $100m in NYSE public offering
#Investment
Opko to activate shelf prospectus to raise $200m
#Investment
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
#Public Trading
Opko Health to delist from TASE
#Public Trading
Opko turns Prolor into Israeli R&D, investment arm
#Acquisition
OPKO Health buys FineTech Pharmaceutical for $27.5m
#Acquisition